-
In category NewsFVR grows its core capabilities in vaccine research
FVR – Finnish Vaccine Research Ltd, one of Europe’s leading commercial vaccine trial service providers, is growing its core competencies by hiring extensive industry and medical expertise. Santtu Heinonen appointedLead Medical ExpertMD, PhD, ORCID >> Santtu is a pediatrician, soon to finalize specialty in pediatric infectious diseases. He has more than 15 years of experience […]
-
In category NewsFVR – Finnish Vaccine Research Ltd’s employee cooperation and change negotiations have been concluded
The employee cooperation and change negotiations related to the organizational restructuring of FVR – Finnish Vaccine Research have been completed. The company started the negotiations in January to strengthen its future operations and growth potential in the global competitive market for vaccine research. As a result of the negotiations, the company will open a new, […]
-
In category NewsFVR joins ImmuDocs doctoral pilot project to increase immunology expertise in Finland
FVR has joined the ImmuDocs pilot project as a consortium partner. The pilot aims to train doctors (PhD) with strong immunology expertise for the pharmaceutical and diagnostic fields. The Finnish Ministry of Education and Culture is funding a national pilot project between 2024 and 2027 to test new doctoral training practices in Finland. In November […]
-
In category News
FVR strengthens its future operations and growth potential through organizational restructuring
FVR – Finnish Vaccine Research Ltd. is planning to restructure its organization in order to strengthen its future operations and growth potential in the global competitive market for vaccine research. FVR has on January 15th, 2024 submitted a proposal for employee cooperation and change negotiations. The planned reorganization focuses on clinical vaccine trial activities at […]
-
In category News
Change in the management team of FVR – Finnish Vaccine Research Ltd: Chief Medical Officer Mika Rämet leaves his duties at FVR
Mika Rämet, M.D., Ph.D., Professor of Paediatrics and Experimental Immunology, and the Chief Medical Officer ofFVR since 2022, is leaving his duties in the company as of 1st of February, 2024. ”We thank Mika warmly for his valuable contribution to the advancement of public health security through high quality, reliable vaccine research,” says Ilkka Haukijärvi, […]
-
In category NewsStudying vaccines for pneumococcal disease
FVR – Finnish Vaccine Research has a team of specialists who have studied pneumococcal disease over several decades. In addition to clinical vaccine trials conducted at our ten research clinics, we specialize in phase 4 vaccine effectiveness and safety studies based on real-world data and use national health registers to study the burden of vaccine-preventable […]
-
In category News
Change of registered official company name
Dear partner, Please note that we have changed our official company name, as registered at the Finnish Patent and Registration Office (PRH). The change means that we have made our former registered auxiliary business name FVR – Finnish Vaccine Research our official primary company name. The business ID and other details remain unchanged. This change […]
-
In category NewsStudying vaccines for CMV (cytomegalovirus)
FVR – Finnish Vaccine Research has a team of specialists who have conducted two major clinical studies of CMV vaccines over several years, enrolling healthy women under 40 years of age. Our track-record of enrolling participants for these studies is good, despite screening criteria that limit the number of qualified participants, such as contact with […]
-
In category NewsWhy partner with FVR – Finnish Vaccine Research in studying vaccines for RSV?
FVR’s unique network of ten clinical vaccine research clinics ensures good capacity and flexibility is available for conducting a successful study. Our expertise covers comprehensive clinical vaccine trials through phases 1-4, including register-based Real-World Evidence studies and large-scale pragmatic field trials, conducted together with healthcare providers. Finland offers an excellent setting for a successful study […]
-
In category News
FVR’s overview of year 2022 has been published
On March 31st 2023, FVR has published an overview of the founding year of the company. You can access the report by clicking the link below. The report includes the following sections: FVR – Finnish Vaccine Research became fully operational on September 1, 2022, when the founding organizations, Tampere University Foundation and the Finnish Institute […]
-
In category NewsGSK announces positive pivotal phase III data for 5-in-1 Meningococcal ABCWY vaccine candidate
On March 14th, 2023, GSK announced positive headline results from the phase III trial (NCT04502693) evaluating the safety, tolerability, and immunogenicity of its MenABCWY combination vaccine candidate, administered as two doses given six months apart in healthy individuals aged 10-25 years. Invasive meningococcal disease (IMD), a major cause of meningitis and septicaemia, is an uncommon […]
-
In category NewsModerna announces mRNA-1345, an investigational Respiratory Syncytial Virus (RSV) vaccine, has met primary efficacy endpoints in phase 3 trial in older adults
On January 17th, Moderna announced positive topline data from its Phase 3 trial of mRNA-1345, an investigational mRNA vaccine targeting respiratory syncytial virus (RSV) in older adults. RSV, a highly contagious seasonal respiratory virus and a leading cause of lower respiratory tract infections and pneumonia, causes a particularly large burden of disease in infants and […]